MARKET

IDXG

IDXG

Interpace Biosciences Inc
OTCQX
2.000
+0.100
+5.26%
Closed 12:39 10/04 EDT
OPEN
2.000
PREV CLOSE
1.900
HIGH
2.000
LOW
1.900
VOLUME
871
TURNOVER
1.69K
52 WEEK HIGH
10.51
52 WEEK LOW
1.570
MARKET CAP
8.39M
P/E (TTM)
-0.5914
1D
5D
1M
3M
1Y
5Y
Interpace Biosciences CFO Thomas Freeburg Resigns
Interpace Biosciences CFO Thomas Freeburg Resigns
MT Newswires · 12h ago
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for impro...
GlobeNewswire · 09/01 21:18
Interpace Biosciences completes sale of pharma services business to Flagship Biosciences
Interpace Biosciences (OTCQX:IDXG) on Wednesday <a href="https://seekingalpha.com/pr/18923525-interpac...
Seekingalpha · 08/31 22:03
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding (DSO) decreased by 15% PARSIPPANY, NJ, Aug. 15, 2022 (GLOBE...
GlobeNewswire · 08/15 20:05
Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M
Interpace Biosciences press release (OTCQX:IDXG): Q1 GAAP EPS of -$0.53. Revenue of $10.38M (+5.6% Y/Y). March 31, 2022 cash balance was $2.9 million, net of restricted cash and May 12,
Seekingalpha · 05/16 20:41
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company...
GlobeNewswire · 05/16 20:15
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Posts Q1 Revenue $10.4M
MT Newswires · 05/16 16:34
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in association with Miroculus, Inc., a developer of revolutionary tool...
GlobeNewswire · 05/11 12:30
More
About IDXG
Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Webull offers kinds of Interpace Biosciences Inc stock information, including OTCQX:IDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDXG stock methods without spending real money on the virtual paper trading platform.